The data on GLP-1 dropout is sobering: a significant fraction of patients who discontinue within the first few months do so during the initial titration period, and most cite side effects as the reason. This is the period when the drug hasn't yet produced visible results but is producing its most pronounced GI effects. It's also when expectations are often most misaligned with what's actually happening pharmacologically.
Most early dropout is preventable. Nearly everything that catches people off guard in the first four weeks could have been anticipated. The goal of this post is to remove as many of those surprises as possible before you take your first injection.
Who shouldn't start
Several absolute contraindications apply to all GLP-1 receptor agonists:
Personal or family history of medullary thyroid carcinoma (MTC): GLP-1 drugs carry a class warning based on rodent studies showing C-cell tumors at suprapharmacological doses. Human epidemiological data does not confirm elevated thyroid cancer rates, but patients with personal or family history of MTC — or Multiple Endocrine Neoplasia type 2 (MEN2), a genetic syndrome that includes MTC — should not use these medications. The genetic risk variants (RET proto-oncogene mutations) are the specific concern.
Prior pancreatitis: Prior pancreatitis is a relative contraindication, not absolute. The GLP-1 class warning on pancreatitis stems from early signals in liraglutide trials; subsequent large trials and post-market data have not confirmed a clear causal elevation in population-level pancreatitis risk. But any history of pancreatitis — whether from gallstones, alcohol, or other causes — warrants explicit discussion with your prescribing provider before starting.
Pregnancy or active conception planning: GLP-1 drugs are not approved for use during pregnancy, and animal data showing adverse fetal effects is sufficient to recommend stopping treatment before conception. The standard recommendation is to stop GLP-1 therapy at least two months before attempting conception. For women of reproductive age, this should be part of the pre-treatment conversation, not a surprise later.
Serious gastroparesis: GLP-1 drugs slow gastric emptying. In patients with pre-existing gastroparesis — significantly delayed gastric emptying from diabetic autonomic neuropathy or other causes — the drug can worsen the condition substantially and is generally contraindicated.
Relative considerations: Severe chronic kidney disease (stage 4–5) and severe hepatic impairment aren't absolute contraindications for all agents in the class, but pharmacokinetics and tolerability are affected enough to warrant specialist input. History of eating disorders — particularly restrictive eating disorders — should be disclosed and discussed; appetite suppression in the context of a prior restrictive eating disorder may not be appropriate without additional monitoring.
Warning(Absolute contraindications to know before your appointment)
Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2): do not start. Prior pancreatitis: discuss explicitly with your provider — this requires individual risk assessment, not a blanket clearance. Pregnancy or planning to conceive within two months: stop treatment first. Serious gastroparesis: discuss with your provider and likely avoid. These are not negotiable starting points; they're the baseline safety screen that needs to happen before the first injection.
Baseline labs to get before starting
Getting labs before your first injection serves two purposes: catching conditions that affect safety or response, and establishing a baseline to compare against as treatment progresses.
TSH (thyroid-stimulating hormone): Hypothyroidism is the most common correctable cause of poor GLP-1 response and is frequently undiagnosed. Knowing your thyroid status before starting means you can attribute subsequent poor response correctly — and treat it — rather than concluding the drug isn't working.
Comprehensive metabolic panel (CMP): Includes kidney and liver function, electrolytes, and glucose. Establishes baseline organ function and catches conditions that affect drug safety or dosing.
Complete blood count (CBC): Baseline hematological picture, useful for tracking over time.
Lipid panel: GLP-1 drugs improve lipid profiles; having a baseline shows the change clearly.
HbA1c or fasting glucose: Relevant even for non-diabetic patients — establishes metabolic baseline and may reveal pre-diabetes that changes the clinical picture.
Fasting insulin: Elevated fasting insulin indicates insulin resistance beyond what HbA1c or fasting glucose captures. This matters for non-response risk assessment.
Vitamin D (25-hydroxyvitamin D): Deficiency is common, independently impairs metabolic response, and is correctable. Know your number before starting so you can supplement appropriately.
Ferritin: Iron stores. Ferritin deficiency (even with normal hemoglobin) causes fatigue and hair telogen effluvium — two things that also happen from rapid weight loss. Knowing your ferritin baseline helps attribute these symptoms correctly later.
Urinalysis: Screens for kidney issues not visible on standard CMP, and for glucosuria if considering SGLT-2 combination.
These labs also give you a before-and-after comparison. The metabolic improvements on GLP-1 therapy — HbA1c, lipids, blood pressure, inflammatory markers — can be dramatic, and having the baseline makes those improvements visible and motivating.
What to tell your provider
Providers can't make informed decisions about GLP-1 safety and interactions without complete information. The things most likely to be under-disclosed:
All current medications: This includes insulin (dose reduction needed when starting GLP-1), sulfonylureas (same — hypoglycemia risk), oral contraceptives (backup method needed for four weeks), levothyroxine (TSH monitoring after starting), and warfarin (closer INR monitoring). Disclose the complete list including OTC drugs.
Supplement use: Berberine (glucose-lowering, hypoglycemia risk in diabetics), high-dose biotin (interferes with lab assays), and any other supplements that affect metabolism or blood glucose.
History of pancreatitis: Even a single episode, even if mild, even if years ago. The mechanism matters; frequency doesn't.
History of gallbladder disease: GLP-1 drugs can increase gallstone risk, particularly during rapid weight loss. Prior gallbladder disease changes the risk calculation.
History of eating disorders: Especially restrictive eating disorders. Appetite suppression medication in this context requires additional monitoring and possibly coordination with mental health providers.
Family history of thyroid cancer or MEN2: The genetic risk is familial; family history matters even without personal history.
Current alcohol use: Relevant to pancreatitis risk discussion and to setting expectations about how alcohol will behave differently on the medication.
Setting realistic expectations
This is where most early dropout is determined — by the gap between what patients expect and what actually happens.
Average outcomes take time. In STEP 1 (semaglutide 2.4mg), average weight loss at 68 weeks was 14.9% of body weight. In SURMOUNT-1 (tirzepatide 15mg), average weight loss at 72 weeks was 20.9%. These are results at maximum dose after more than a year of treatment. They are not week-eight results, and they are not starting-dose results.
The first month is titration, not treatment. Starting semaglutide at 0.25mg or tirzepatide at 2.5mg — the initial doses — is primarily about establishing tolerability. Weight loss at these doses is modest or minimal. The drug isn't at therapeutic range yet.
Not everyone responds identically. The 14.9% and 20.9% averages have substantial variance around them. Some people lose significantly more; some lose less. Comparing your month-two results to someone else's month-twelve transformation generates expectations that have no basis in your own pharmacokinetics and starting point.
Side effects are real and temporary for most people. Nausea in the first several weeks is extremely common — in STEP 1, reported by over 40% of patients. The majority resolve or become manageable within the first two to three months. This requires getting through the early weeks, which is harder when you're not prepared for them.
Intuition(The first four weeks are the hardest, not the representative experience)
Many people who quit during the first month make their assessment during the worst pharmacological window — when side effects are most pronounced and weight loss is least evident, because the dose is still sub-therapeutic. The question isn't whether the first four weeks feel good. It's whether the next twelve months at therapeutic dose will produce the outcome. Those are different questions, and answering the second one from data gathered during the first requires understanding what's actually happening during the titration phase.
What to have ready before you start
A protein source you can tolerate when solid food isn't appealing. Nausea on a GLP-1 makes some solid proteins difficult to eat consistently. A protein powder — ideally tested in advance to find one that doesn't worsen nausea — allows you to hit protein targets when you can't stomach a chicken breast. Unflavored whey or a mildly flavored option works better for many people than strongly flavored or artificially sweetened versions.
A nausea management plan. Small, frequent meals (instead of large, infrequent ones) reduce the load on a slowed stomach. Ginger tea or ginger chews have evidence for nausea reduction. Eating slowly and avoiding lying down immediately after eating helps. If your provider is willing, a short prescription for ondansetron (Zofran) for the early weeks gives you a pharmaceutical option when dietary adjustments aren't enough.
A bowel management routine. GLP-1 drugs cause constipation more commonly than diarrhea in most patients. Having adequate hydration (2+ liters of water daily), fiber-rich foods or a psyllium supplement, and MiraLAX (polyethylene glycol, available OTC) as needed prevents constipation from becoming a significant quality-of-life problem during the first weeks.
A consistent injection day and time. Weekly injections work best with consistent scheduling. Choose a day and time that fits your routine and that you'll maintain week over week. Many patients choose Friday or Saturday because any first-dose side effects arrive over a weekend when they're not working. Others choose weekdays to keep side effect monitoring in a structured schedule. There's no pharmacologically superior day — it's about what you'll actually maintain.
The first four weeks: what to expect
Week 1: At the starting dose, pharmacological effects are minimal for most patients. Some people notice appetite changes immediately; most don't feel much. Some people experience nausea with the first injection even at starting dose — this is a genuine drug effect, not anxiety. Don't interpret minimal effects as evidence the drug won't work.
Weeks 2–3: Often the hardest. The dose is still sub-therapeutic, but GI side effects — nausea, constipation, occasional vomiting, fullness with small amounts of food — are present and sometimes uncomfortable. This is the peak dropout period. Weight loss is modest if any. Food aversions may begin appearing — specific foods that were previously fine now smell or taste unappealing.
Week 4 and beyond: For most patients, GI side effects begin to ease. The body adapts to slowed gastric emptying. Appetite suppression becomes more consistent. The second dose escalation (to semaglutide 0.5mg or tirzepatide 5mg) may produce a brief recurrence of early side effects.
The transition from weeks 2–3 to week 4 is the hurdle. It requires knowing in advance that it's coming, having a plan for the side effects, and having calibrated expectations that prevent the conclusion that something is wrong.
Mistakes to avoid from day one
Escalating dose while still significantly nauseous: Dose escalation while GI side effects are not under control typically worsens them. Most protocols allow staying at the current dose longer if needed. Notify your provider about uncontrolled nausea before the scheduled escalation.
Skipping meals entirely rather than eating small: Completely empty stomach worsens nausea on GLP-1s. Small, low-fat meals eaten slowly prevent the severe nausea that comes from both eating too much at once and eating nothing. This is counterintuitive — when nauseous, not eating feels like the right response — but the empty stomach approach usually backfires.
Not tracking protein specifically. Total calorie tracking on a GLP-1 is often less useful than tracking protein specifically. Most patients eat well under their calorie target without effort; the limiting factor becomes protein. Track that number explicitly.
Comparing too early. If you're following someone on social media who shows dramatic transformation photos, confirm how long they've been on the medication and at what dose before you benchmark against their progress.
Not telling your provider about side effects. Providers can help: they can adjust escalation timing, prescribe antiemetics, troubleshoot constipation, and assess whether what you're experiencing is expected versus a signal that something needs attention. The information they need comes from you reporting symptoms accurately.
User Sentiment
The before-you-start community discussions are among the most practically useful in GLP-1 forums — because people who've been through the early weeks know exactly what to tell the people starting.
Example(What the community says)
The near-universal pre-start advice from experienced members: "Eat small. Go slow. Don't skip your protein. The nausea gets better." The protein powder recommendation circulates constantly — specific brands that tolerate poorly-seasoned palates are shared with the enthusiasm of product reviews. The constipation warning appears in almost every "I'm starting next week" thread. The most common retrospective regret from people who quit early and then restarted: "I didn't know the first month wasn't representative. I thought that was what it was always going to feel like." The people who quit during weeks 2–3 and came back often describe the second start as dramatically easier because expectations were calibrated.
Who It's For
This post is for anyone in the pre-start phase — deciding whether to start, preparing for their first injection, or in the first few weeks and struggling. It's also useful for anyone who previously tried a GLP-1 and stopped early, who may want to understand what they could do differently for a second attempt.
The most important framing: the first four weeks are not a representative sample of the treatment experience. They're the highest-side-effect, lowest-dose, lowest-weight-loss period of a treatment that produces its results over twelve to eighteen months.
Summary(The short version)
Absolute contraindications before starting: personal or family history of medullary thyroid carcinoma or MEN2 (don't start), prior pancreatitis (discuss with provider), pregnancy or planning to conceive within two months (stop before conception), serious gastroparesis (discuss, likely avoid). Get baseline labs before your first injection: TSH, CMP, CBC, lipids, HbA1c or fasting glucose, fasting insulin, vitamin D, ferritin, urinalysis. Tell your provider all medications (especially insulin, sulfonylureas, oral contraceptives, levothyroxine, warfarin) and any history of pancreatitis, gallbladder disease, or eating disorders. Realistic expectations: average 15–21% weight loss takes 12–18 months at maximum dose; the first month is titration, not treatment. Have ready before starting: a tolerable protein powder, a nausea plan (small meals, ginger, ondansetron if available), a bowel routine (hydration, fiber, MiraLAX), and a consistent injection day. The first four weeks — especially weeks 2–3 — are the hardest period. GI side effects are most pronounced, weight loss is minimal, and most early dropout happens here. This period ends. Most patients who get through it report a substantially different experience from month two onward.